A sweeping review of 110 clinical trials now points to higher death odds in adults treated with cefepime compared with other common antibiotics, and the signal refuses to go away.
Story Snapshot
- A 2026 meta-analysis found a 94.4% probability that cefepime raises mortality versus other beta-lactams.
- Published randomized trials showed stronger harm, with a 98.6% probability and an odds ratio of 1.17.
- The risk signal appears concentrated in adults; children did not show increased risk in reports.
- Earlier U.S. Food and Drug Administration reviews did not confirm a significant mortality increase, keeping debate alive.
What the new evidence actually says about cefepime and death
Researchers pooled 110 randomized trials with 22,608 patients and asked a simple question: do more people die on cefepime than on other beta-lactams? The answer, framed in Bayesian terms, was yes, with a 94.4% probability of higher mortality.
The pooled odds ratio was 1.10, with a 95% credible interval from 0.98 to 1.24, which leaves some uncertainty but tilts toward harm. Media summaries reported that the mortality signal sat in adults, not in children, sharpening the clinical focus.
The signal was stronger when the analysis looked only at published, peer-reviewed randomized trials. In that subset of 73 trials with over 15,000 patients, the odds ratio rose to 1.17, and the probability of increased mortality hit 98.6%.
Coverage also translated this into an everyday yardstick: about one extra death for every 111 adults treated in those published trials, and about one in 227 across all trials combined. Those are small absolute numbers, but they matter when hospitals treat thousands.
Why adults, why now, and how big is the real risk?
The adult-only focus likely reflects how cefepime behaves in older or sicker bodies. Drug levels rise when kidneys slow down. Cefepime can cause neurotoxicity at high exposures, which might worsen outcomes in fragile patients.
The 2026 paper did not prove a mechanism, but it noted higher doses, such as two grams every 12 hours, tracked with the signal across different infections and comparator drugs. That breadth hints this is not a fluke of one disease or a single rival antibiotic.
Clinicians must weigh modest absolute risk against the need to hit dangerous bacteria fast. Broad-spectrum beta-lactams save lives when sepsis strikes. Yet choice within the class often exists.
If two options cover the likely germs, and one shows a repeated mortality signal in adults across decades of data, prudence says pause and check the dose, the kidneys, and the alternatives. That is not panic; that is common-sense stewardship.
What earlier reviews and regulators said, and why debate persists
The controversy is not new. A 2007-era meta-analysis linked cefepime to higher all-cause mortality, with a risk ratio of 1.26.
The Food and Drug Administration then reviewed a larger dataset, including unpublished trials, and reported no statistically significant mortality difference at 30 days in either trial-level or patient-level analyses. An Oxford Academic commentary echoed that view and urged caution in blaming the drug outright.
The new analysis reopens the case by using Bayesian methods, which answer “how likely” rather than “is it statistically significant.” On the full 110-trial set, the credible interval crosses neutrality, which gives critics room to argue the effect may be small or unstable.
But the high probability of harm, the stronger published-trial signal, and the adult focus keep the concern alive. This is the classic drug-safety tug-of-war over mixed datasets and evolving methods.
How to act now without overreacting
Hospitals do not need a headline to change a formulary. They need a plan. Start with adult risk management: avoid high-dose cefepime in patients with reduced kidney function unless no equal alternative exists; check drug levels when possible; tighten renal dosing and monitor for confusion or seizures.
When coverage options are similar, prefer agents with neutral mortality track records in adults.
A massive new review of medical data published in JAMA Network Open has brought renewed attention to cefepime, a widely utilized antibiotic for severe bacterial infections. Researchers analyzing over 100 historical clinical trials involving more than 22,500 patients identified a… pic.twitter.com/cZ3CKqHxAP
— Science & Nature (@ScienceIsNew) September 15, 2026
Policy leaders should ask for two near-term steps. First, an individual patient data reanalysis of the 110 trials to test whether kidney function, intensive care status, or dosing explains the signal.
Second, comparator-specific summaries against piperacillin-tazobactam and meropenem, the two workhorses that often stand in for cefepime.
If the adult mortality edge holds after those filters, guidelines should tilt accordingly. If it fades, dosing and patient selection may be the fix.
Sources:
foxnews.com, pubmed.ncbi.nlm.nih.gov, medpagetoday.com
